Skip to main content

Table 1 Characteristics and treatments of the included studies

From: Meta-analysis of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced rectal cancer

Author/year Country Arm No. of Pts Treatment regimens Type of surgery Duration Design Median age (years) Clinical T category (T2/T3/T4) Clinical N category (N0/N1/N2/N3) Clinical stage (I/II/III/IV) Follow-up (months) pCR R0 NOS
Matsumoto, 2015 [17] Japan NAC 15 FOLFOX: 6 cycles, IRIS: 3 cycles, FOLFIRI: 5 cycles LAR (12), APR/ASR (2), ISR (1) 2005–2010 Retrospective 64 (56–68) 0/12/3 NA NA 44.2 (30.7–59.5) 2 15 7
NACRT 109 NA LAR (75), APR/ASR (22), ISR (3)    67 (61–74) 0/92/17 NA NA   0 105  
Sakuyama, 2016 [26] Japan NAC 44 FOLFOX: 6 cycles ISR (34), other (10) 2001–2014 Retrospective 57.4 (28–76) 0/38/6 5/16/7/16 0/5/35/4 NA 4 NA 7
NACRT 44 5FU+RT (45 Gy/25 F) ISR (44)    56 (27–77) 9/35/0 27/10/6/1 6/19/29/0   9 NA  
Okuyama, 2018 [18] Japan NAC 27 SOX+cetuximab, SOX+mFOLFOX6 LAR (19), APR (8) 2010–2016 Retrospective 66 (40–79) 0/24/3 0/18/9/0 NA 45.4 1 26 6
NACRT 28 5FU+RT (45 Gy/25 F) LAR (8), APR (20)    68 (42–78) 0/22/5 0/17/11/0 NA   4 26  
Sada, 2018 [27] American NAC 410 NA NA 2006–2010 Retrospective NA NA NA NA NA 35 NA 5
NACRT 11614 NA NA    NA NA NA NA   1352 NA  
Sato, 2019 [28] Japan NAC 16 SOX:S1+Ox: 3 cycles Laparoscopically 2002–2016 Retrospective 67.5 (43–77) NA NA NA NA 2 NA 8
NACRT 10 5FU+RT (40–45Gy) Laparotomy    66 (53–71) NA NA NA   0 NA  
Deng, 2019 [29] China NAC 165 mFOLFOX6 NA 2010–2015 RCT 54.1 1/114/50 46/76/43/0 0/46/119/0 NA 10 136 7
NACRT 330 5FU/mFOLFOX6+RT (46–50.4 Gy/23–25 F) NA    54.1/52.1 11/206/113 67/172/91 0/67/263/0   61 262  
  1. Note: No. of Pts Number of patients, RCT randomized controlled trial, pCR pathologic complete response, NAC neoadjuvant chemotherapy without radiation, NACRT neoadjuvant chemoradiotherapy, 5FU 5-fluorauracil, OX oxaliplatin, RT radiotherapy, FOLFOX fluorouracil, leucovorin, and oxaliplatin, IRIS irinotecan, tegafurgimeracil-oteracil potassium, FOLFIRI fluorouracil, leucovorin, and irinotecan, SOX S-1+ oxaliplatin, S-1 tegafurgimeracil-oteracil potassium, mFOLFOX6 modified infusional fluorouracil, leucovorin, and oxaliplatinm, XELOX capecitabine + oxaliplatinm, APR, abdominoperineal resection, ISR intersphincteric resection, LAR low anterior resection, ASR abdominosacral resection, NOS Newcastle-Ottawa Scale, NA not available